Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, May 19, 2015, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,088.06 to $96,569,200.00.

Highlighted Stocks Traded by Insiders:

Repligen (RGEN) - FREE Research Report

Rusche James R, who is Senior Vice President at Repligen, sold 15,000 shares at $41.32 on May 19, 2015. Following this transaction, the Senior Vice President owned 96,849 shares meaning that the stake was reduced by 13.41% with the 15,000-share transaction.

The shares most recently traded at $41.55, up $0.23, or 0.55% since the insider transaction. Historical insider transactions for Repligen go as follows:

  • 4-Week # shares bought: 35,000
  • 4-Week # shares sold: 170,000
  • 12-Week # shares bought: 35,000
  • 12-Week # shares sold: 270,869
  • 24-Week # shares bought: 35,000
  • 24-Week # shares sold: 270,869

The average volume for Repligen has been 440,200 shares per day over the past 30 days. Repligen has a market cap of $1.4 billion and is part of the health care sector and drugs industry. Shares are up 110.66% year-to-date as of the close of trading on Tuesday.

Repligen Corporation, a life sciences company, develops, manufactures, and markets consumable bioprocessing products for use in the production of monoclonal antibodies and other biologic drugs. The company has a P/E ratio of 198.7. Currently, there are 2 analysts who rate Repligen a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RGEN - FREE

TheStreet Quant Ratings rates Repligen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Repligen Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

DaVita HealthCare Partners (DVA) - FREE Research Report

Zumwalt Leanne M, who is Grp VP Purch & Public Affairs at DaVita HealthCare Partners, sold 538 shares at $82.49 on May 19, 2015. Following this transaction, the Grp VP Purch & Public Affairs owned 6,733 shares meaning that the stake was reduced by 7.4% with the 538-share transaction.

Mildenberger Laura, who is Chief People Ofcr, Kidney Care at DaVita HealthCare Partners, sold 461 shares at $82.75 on May 19, 2015. Following this transaction, the Chief People Ofcr, Kidney Care owned 6,273 shares meaning that the stake was reduced by 6.85% with the 461-share transaction.

The shares most recently traded at $83.09, up $0.34, or 0.41% since the insider transaction. Historical insider transactions for DaVita HealthCare Partners go as follows:

  • 4-Week # shares sold: 571
  • 12-Week # shares sold: 571
  • 24-Week # shares sold: 1,682

The average volume for DaVita HealthCare Partners has been 1.2 million shares per day over the past 30 days. DaVita HealthCare Partners has a market cap of $17.8 billion and is part of the health care sector and health services industry. Shares are up 9.85% year-to-date as of the close of trading on Tuesday.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates in two divisions, Kidney Care and HealthCare Partners. The company has a P/E ratio of 42.2. Currently, there are 6 analysts who rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DVA - FREE

TheStreet Quant Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full DaVita HealthCare Partners Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Fleetcor Technologies (FLT) - FREE Research Report

House Todd, who is President NA Card Products at Fleetcor Technologies, sold 7,000 shares at $154.33 on May 19, 2015. Following this transaction, the President NA Card Products owned 6,041 shares meaning that the stake was reduced by 53.68% with the 7,000-share transaction.

The shares most recently traded at $152.82, down $1.51, or 0.99% since the insider transaction. Historical insider transactions for Fleetcor Technologies go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 5,000
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 5,000
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 41,235

The average volume for Fleetcor Technologies has been 556,600 shares per day over the past 30 days. Fleetcor Technologies has a market cap of $14.2 billion and is part of the services sector and diversified services industry. Shares are up 3.19% year-to-date as of the close of trading on Tuesday.

FleetCor Technologies, Inc. provides fuel cards and workforce payment products and services in North America, Latin America, Europe, Australia, and New Zealand. The company has a P/E ratio of 35.4. Currently, there are 6 analysts who rate Fleetcor Technologies a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FLT - FREE

TheStreet Quant Ratings rates Fleetcor Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, compelling growth in net income, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Fleetcor Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.